DUBLIN--(BUSINESS WIRE)--The "Global Smoking Cessation Aids Market - Trend & Forecast 2017 - 2022" report has been added to Research and Markets' offering.
The market for smoking cessation aids have been segmented into NRT Gums, NRT Lozenges, NRT Inhalers, NRT Patches, Sprays, Drugs and electronic cigarettes. Nicotine replacement therapy has the largest market segment with many OTC products.
Large Tobacco Consuming Population, Awareness amongst Smokers on hazards of smoking, Banning of Tobacco product advertisement in many countries are the key factors augmenting the market as market driver.
Amongst NRT products, NRT Gums has the largest share in the market. Amongst prescription products, inhalers, and sprays have the largest market. However, there is a rapid growth in electronic cigarettes, NRT lozenges, and NRT patches market due to ease of use. The drug therapy for Smoking cessation did not have a good impact.
Amongst drugs Zyban by GSK and Chantix by Pfizer are used as first line therapy. However, due to many adverse effects of these drugs like suicidal tendency etc., there have been a decline in market of drug as a smoking cessation aid.
The key players in smoking cessation therapy market are GlaxoSmithKline, Pfizer, Novartis, Johnson and Johnson, Cipla Ltd. And others.
Key Topics Covered:
2. Executive Summary
3. Market Overview
4. Market Segmentation
5. Global Market: Geographical Landscape
6. Competitive landscape
7. Key Players
- Reckitt Benckiser Plc
- GlaxoSmithKline Plc
- Johnson and Johnson
- Bayer AG
- Cipla Ltd.
- Takeda Pharmaceuticals Co. Ltd.
For more information about this report visit https://www.researchandmarkets.com/research/xp7lfr/global_smoking